Q4 2025 Repligen Corp Earnings Call Transcript
Key Points
- Repligen Corp (RGEN) achieved 14% organic growth in the fourth quarter and 16% for the full year 2025, exceeding their initial guidance.
- The company saw significant growth in its proteins and process analytics segments, both exceeding 30% growth in the fourth quarter.
- Repligen Corp (RGEN) expanded its adjusted operating margin by 90 basis points to 13.8% in 2025, with a 240 basis point expansion excluding M&A and foreign currency impacts.
- The company launched several new products in 2025, including the SoloVPE PLUS and ProConnex MixOne, and plans to continue innovating in 2026.
- Repligen Corp (RGEN) has a strong balance sheet with $768 million in cash and marketable securities, providing flexibility for potential acquisitions.
- Capital equipment revenue was flat year-over-year due to a tough comparison, indicating challenges in this segment.
- The company faces a two-point headwind from a gene therapy platform in its 2026 guidance.
- There is uncertainty around FDA policy and biopharma strategic responses, which could impact future growth.
- Repligen Corp (RGEN) noted muted demand for downstream systems, which could affect future revenue growth.
- The company is facing potential tariff surcharges, which could impact revenue and margins in 2026.
Ladies and gentlemen, thank you for standing by. My name is Jerico, and I will be your conference operator today. At this time, I would like to welcome everyone to the Repligen fourth quarter 2025 earnings call. (Operator Instructions) I would now like to turn the conference over to Jacob Johnson, Vice President, Investor Relations. You may begin.
Thank you, operator, and welcome, everyone, to our 2025 fourth quarter report. On this call, we will cover business highlights and financial performance for the 3 and 12-month periods ended December 31, 2025, and we will provide financial guidance for the full year 2026. Joining us on the call today are Repligen's President and Chief Executive Officer, Olivier Loeillot; and our Chief Financial Officer, Jason Garland.
As a reminder, the forward-looking statements that we make during this call, including those regarding our business goals and expectations for the financial performance of the company, are subject to risks and uncertainties that
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
